These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 12721933)

  • 21. Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia.
    Wolday D; Legesse D; Kebede Y; Siraj DS; McBride JA; Striker R
    PLoS One; 2020; 15(10):e0240880. PubMed ID: 33091053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss.
    Hazenberg MD; Otto SA; Wit FW; Lange JM; Hamann D; Miedema F
    AIDS; 2002 Jun; 16(9):1287-9. PubMed ID: 12045496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
    Khoury G; Fromentin R; Solomon A; Hartogensis W; Killian M; Hoh R; Somsouk M; Hunt PW; Girling V; Sinclair E; Bacchetti P; Anderson JL; Hecht FM; Deeks SG; Cameron PU; Chomont N; Lewin SR
    J Infect Dis; 2017 Mar; 215(6):911-919. PubMed ID: 28453847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.
    Papasavvas E; Sandberg JK; Rutstein R; Moore EC; Mackiewicz A; Thiel B; Pistilli M; June RR; Jordan KA; Gross R; Maino VC; Nixon DF; Montaner LJ
    J Infect Dis; 2003 Sep; 188(6):873-82. PubMed ID: 12964119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
    Hunt PW; Brenchley J; Sinclair E; McCune JM; Roland M; Page-Shafer K; Hsue P; Emu B; Krone M; Lampiris H; Douek D; Martin JN; Deeks SG
    J Infect Dis; 2008 Jan; 197(1):126-33. PubMed ID: 18171295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.
    Okulicz JF; Le TD; Agan BK; Camargo JF; Landrum ML; Wright E; Dolan MJ; Ganesan A; Ferguson TM; Smith DM; Richman DD; Little SJ; Clark RA; He W; Ahuja SK
    JAMA Intern Med; 2015 Jan; 175(1):88-99. PubMed ID: 25419650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.
    Karlsson AC; Younger SR; Martin JN; Grossman Z; Sinclair E; Hunt PW; Hagos E; Nixon DF; Deeks SG
    AIDS; 2004 Apr; 18(7):981-9. PubMed ID: 15096800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of in vitro stimulation with lipopolysaccharide on T-cell activation in HIV-infected antiretroviral-treated patients.
    Tincati C; Bellistrì GM; Ancona G; Merlini E; d'Arminio Monforte A; Marchetti G
    Clin Dev Immunol; 2012; 2012():935425. PubMed ID: 22400042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
    BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.
    Wellons MF; Ottinger JS; Weinhold KJ; Gryszowka V; Sanders LL; Edwards LJ; Gooding ME; Thomasch JR; Bartlett JA
    J Infect Dis; 2001 May; 183(10):1522-5. PubMed ID: 11319689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
    Deeks SG; Barbour JD; Grant RM; Martin JN
    AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
    Yukl SA; Gianella S; Sinclair E; Epling L; Li Q; Duan L; Choi AL; Girling V; Ho T; Li P; Fujimoto K; Lampiris H; Hare CB; Pandori M; Haase AT; Günthard HF; Fischer M; Shergill AK; McQuaid K; Havlir DV; Wong JK
    J Infect Dis; 2010 Nov; 202(10):1553-61. PubMed ID: 20939732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
    Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
    Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.